药械

订阅

MedSci主页 / 所有栏目 / 药械

康哲药业斥资5亿美元获得阿斯利康两款心血管药物商业化权利

2016-03-02 佚名 生物谷

康哲药业阿斯利康心血管药物
关注

近日，阿斯利康发布消息称，将其旗下抗心绞痛药物依姆多（Imdur）和抗高血压药物波依定（Plendil）的部分商业化权利以5亿美元转让给康哲药业（China Medical System,CMS）。 按照协议，康哲药业将向阿斯利康支付3.1亿美元，以此获得波依定在中国范围内销售的权利，但波依定的生产供应权利仍归阿斯利康所有。 阿斯利康全球执行副总裁Mark Mallon表示，与康哲的商业化合作

近日，阿斯利康发布消息称，将其旗下抗心绞痛药物依姆多（Imdur）和抗高血压药物波依定（Plendil）的部分商业化权利以5亿美元转让给康哲药业（China Medical System,CMS）。

按照协议，康哲药业将向阿斯利康支付3.1亿美元，以此获得波依定在中国范围内销售的权利，但波依定的生产供应权利仍归阿斯利康所有。

阿斯利康全球执行副总裁Mark Mallon表示，与康哲的商业化合作，将有助于让更多患者有机会获得药物治疗，同时也确保公司能将更多精力投掷于重点领域的新药创制，以实现长期稳健型盈利。

协议中还规定，阿斯利康将其旗下抗心绞痛药物依姆多的全球商业权利（除美国外）以1.9亿美元高价转让给康哲药业及其控股的西藏诺迪康药业。

依姆多

阿斯利康一款口服缓释片，主要成分为单硝酸异山梨酯，用于预防和治疗冠状动脉疾病引起的心绞痛。

波依定

阿斯利康一款口服缓释片，主要成分为非洛地平（钙离子拮抗剂），用于治疗高血压和预防慢性稳定型心绞痛。

康哲药业

康哲药业（简称「CMS」）是一家立足中国的医药服务公司，致力于为海外及国内专业制药企业处方药品的营销、推广及销售提供服务，旗下控股多家医药科技公司和医药服务公司。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771713, encodeId=48c91e7171302, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Mon Jun 27 19:35:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646028, encodeId=0d2d1646028b8, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Wed Nov 23 01:35:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69214, encodeId=7d7069214b1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69215, encodeId=86606921541, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69216, encodeId=e7686921679, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69217, encodeId=97506921e5d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506750, encodeId=7f981506e50a4, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Fri Mar 04 04:35:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-06-27 zhangxingru

    #商业#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1771713, encodeId=48c91e7171302, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Mon Jun 27 19:35:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646028, encodeId=0d2d1646028b8, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Wed Nov 23 01:35:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69214, encodeId=7d7069214b1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69215, encodeId=86606921541, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69216, encodeId=e7686921679, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69217, encodeId=97506921e5d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506750, encodeId=7f981506e50a4, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Fri Mar 04 04:35:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-11-23 jiafufeng@yaho

    #心血管药物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1771713, encodeId=48c91e7171302, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Mon Jun 27 19:35:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646028, encodeId=0d2d1646028b8, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Wed Nov 23 01:35:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69214, encodeId=7d7069214b1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69215, encodeId=86606921541, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69216, encodeId=e7686921679, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69217, encodeId=97506921e5d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506750, encodeId=7f981506e50a4, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Fri Mar 04 04:35:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-14 忠诚向上

    好好学习，继续研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1771713, encodeId=48c91e7171302, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Mon Jun 27 19:35:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646028, encodeId=0d2d1646028b8, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Wed Nov 23 01:35:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69214, encodeId=7d7069214b1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69215, encodeId=86606921541, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69216, encodeId=e7686921679, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69217, encodeId=97506921e5d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506750, encodeId=7f981506e50a4, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Fri Mar 04 04:35:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-14 忠诚向上

    好好学习，继续研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1771713, encodeId=48c91e7171302, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Mon Jun 27 19:35:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646028, encodeId=0d2d1646028b8, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Wed Nov 23 01:35:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69214, encodeId=7d7069214b1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69215, encodeId=86606921541, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69216, encodeId=e7686921679, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69217, encodeId=97506921e5d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506750, encodeId=7f981506e50a4, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Fri Mar 04 04:35:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-14 忠诚向上

    好好学习，继续研究

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1771713, encodeId=48c91e7171302, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Mon Jun 27 19:35:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646028, encodeId=0d2d1646028b8, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Wed Nov 23 01:35:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69214, encodeId=7d7069214b1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69215, encodeId=86606921541, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69216, encodeId=e7686921679, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69217, encodeId=97506921e5d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506750, encodeId=7f981506e50a4, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Fri Mar 04 04:35:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-14 忠诚向上

    好好学习，继续研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1771713, encodeId=48c91e7171302, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Mon Jun 27 19:35:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646028, encodeId=0d2d1646028b8, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Wed Nov 23 01:35:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69214, encodeId=7d7069214b1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69215, encodeId=86606921541, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69216, encodeId=e7686921679, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69217, encodeId=97506921e5d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:02:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506750, encodeId=7f981506e50a4, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Fri Mar 04 04:35:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-04 yeaweam

    #商业化#

    0